Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 19, Issue 4, pp. 565-572
PubMed
Published By
Print ISSN
Online ISSN
History
- Received November 17, 2020
- Revision received December 16, 2020
- Accepted February 10, 2021
- Published first February 16, 2021.
Article Versions
- Previous version (February 16, 2021 - 05:51).
- Previous version (March 4, 2021 - 06:43).
- You are viewing the most recent version of this article.
Copyright & Usage
©2021 American Association for Cancer Research.
Author Information
- Alex O. Haber1,2,
- Aditi Jain1,2,
- Chinnadurai Mani3,
- Avinoam Nevler1,2,
- Lebaron C. Agostini1,2,
- Talia Golan4,5,
- Komaraiah Palle3,
- Charles J. Yeo1,2,
- William H. Gmeiner6,#,*, and
- Jonathan R. Brody7,#,*
- 1The Jefferson Pancreas, Biliary and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.
- 2Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
- 3Texas Tech University Health Sciences Center, Lubbock, Texas.
- 4Oncology Institute, Chaim Sheba Medical Center, Tel Aviv, Israel.
- 5Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- 6Deparment of Cancer Biology, Wake Forest School of Medicine, Wake Forest University, Winston-Salem, North Carolina.
- 7Department of Surgery and Cell, Developmental and Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
- ↵*Corresponding Authors:
Jonathan R. Brody, Department of Surgery Oregon Health & Science University, Portland, OR 97239. E-mail: brodyj{at}ohsu.edu; and William H. Gmeiner, bgmeiner{at}wakehealth.edu
↵#W.H. Gmeiner and J.R. Brody contributed equally to this article.
April 2021
Volume 19, Issue 4
Volume 19, Issue 4
AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with PARG Inhibition
Jump to section
Advertisement